
By Dr. Leandro Pucci, DCN, CNS, CKNS, LDN
Outside the GLP-1 class, only one metabolic peptide, tesamorelin, has randomized human trials showing a meaningful change in a clinical outcome, and those trials were in a specific population. Growth hormone secretagogues reliably raise growth hormone and IGF-1, but raising a hormone level is not the same as improving health. MOTS-c and BPC-157 are promising in animal studies and largely untested in controlled human trials. In July 2026 an FDA advisory panel voted to allow pharmacies to compound several of these peptides, against the advice of FDA staff. That vote addressed access, not effectiveness.
Patients bring me questions about these peptides every week, usually after reading confident claims online. This article grades each one by the strength of human evidence, explains the mechanism, and is direct about what is not yet known. For background on what peptides are and how the GLP-1 class compares, start with my guide to peptides for metabolic health.
Three questions sort most claims quickly.
Tesamorelin is a modified version of growth hormone-releasing hormone (GHRH). It prompts the pituitary to release more of the body's own growth hormone, which preferentially mobilizes visceral fat. It is FDA-approved for reducing excess abdominal fat in adults with HIV.
In the pivotal trial, 412 adults with HIV and abdominal fat accumulation received tesamorelin or placebo for 26 weeks. Visceral fat fell 15.2% with tesamorelin and rose 5.0% with placebo. Triglycerides fell by 50 mg/dL, IGF-1 rose by 81%, and glucose measures did not change significantly (1). In a later 12-month trial in adults with HIV and fatty liver, tesamorelin reduced liver fat by 37% relative to baseline, and 35% of treated participants reached normal liver fat compared with 4% on placebo (2).
These are real, outcome-level results. The limitation is population: HIV-associated fat accumulation has its own drivers. Using tesamorelin for visceral fat in otherwise healthy adults is off-label and has not been tested in comparable trials.
This group either mimics GHRH (CJC-1295, sermorelin) or mimics ghrelin at the growth hormone secretagogue receptor (ipamorelin, GHRP-2, GHRP-6). They are often combined on the premise that hitting both receptors amplifies the growth hormone pulse.
The pharmacology is well documented. A single injection of CJC-1295 in healthy adults raised growth hormone 2- to 10-fold for six days or more and IGF-1 1.5- to 3-fold for 9 to 11 days (3). Ipamorelin was developed as a selective secretagogue that raised growth hormone without raising cortisol, a selectivity shown in animal studies (4).
What is missing is outcome data. The most informative human trial in this class tested MK-677, an oral ghrelin mimetic (not a peptide, but the same receptor). Over a year in 65 healthy adults aged 60 to 81, it raised growth hormone and IGF-1 to young-adult levels and increased fat-free mass by 1.1 kg. It did not reduce visceral or total fat, did not improve strength or function, raised fasting glucose by about 5 mg/dL, and reduced insulin sensitivity (5).
That trade-off matters for a metabolic practice. In someone who is already insulin resistant, raising growth hormone can push glucose in the wrong direction. It is one reason I want fasting insulin and A1c before and during any growth hormone-axis peptide.
MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA. In mice, it acts mainly on skeletal muscle, activates AMPK (the cell's energy sensor), and prevented both diet-induced obesity and age-related insulin resistance (6). Exercise raises MOTS-c levels in human muscle and blood, and in older mice, MOTS-c treatment improved physical capacity (7).
That is a coherent story linking mitochondrial signaling, exercise, and insulin sensitivity. It has not been tested in controlled human trials with metabolic outcomes. When the FDA reviewed MOTS-c for compounding in 2026, agency staff recommended against it, citing limited evidence (9, 10). Until that changes, I treat MOTS-c as a research question, and I point patients toward the intervention that reliably raises it: training.
BPC-157 is a 15-amino-acid fragment derived from a protein in gastric juice. Most of its literature comes from rodent models of gut injury, tendon and ligament damage, and wound healing, much of it from a small number of laboratories (8). TB-500 is a fragment of thymosin beta-4, studied mainly for wound and tissue repair. Neither has been tested in large, controlled human trials, and neither has a primary metabolic mechanism.
They appear in metabolic conversations because people with insulin resistance often also have joint pain, gut symptoms, or slow recovery from training. Those problems deserve evaluation, but the case for these peptides as treatments rests on animal data.
In July 2026 the FDA's Pharmacy Compounding Advisory Committee reviewed seven peptides for the list of substances pharmacies may compound. FDA staff reviewers recommended against all of them, citing limited evidence. The committee voted narrowly in favor of six, including BPC-157 (8 to 6), TB-500 (8 to 6), and MOTS-c (7 to 5) (9, 10). The votes are advisory. Formal rulemaking is required before any of these can be routinely compounded, and in October an FDA interim access policy for certain peptides went to the White House for review without published text (11). None of these peptides is an FDA-approved drug. Products sold online as "research use only" are outside any pharmacy oversight.
Tesamorelin: Randomized clinical trials in adults with HIV have shown reductions in visceral fat and liver fat. However, its effectiveness in people without HIV remains less established.
CJC-1295: Small dose-finding studies in humans have demonstrated increases in growth hormone (GH) and IGF-1 levels. These are surrogate markers, and more research is needed to determine whether these changes translate into meaningful improvements in body composition or metabolic health.
Ipamorelin: Early human pharmacology studies have shown increases in growth hormone levels. However, its effects on actual health outcomes and its long-term safety remain unknown.
MOTS-c: Current evidence is limited to animal research, primarily in mice. Whether these findings translate into meaningful metabolic benefits in humans has not yet been established.
BPC-157 and TB-500: Human evidence is very limited, consisting mainly of case reports and small, uncontrolled studies. There is currently no strong clinical evidence demonstrating metabolic benefits, and both their effectiveness and safety in humans remain uncertain.
The patients most likely to benefit from any of these peptides are the ones least likely to need them first: people whose sleep, protein intake, training, and insulin sensitivity are already in good order. When those foundations are missing, fixing them produces larger and more durable changes than any compound on this list. When they are in place and a specific target remains (visceral fat that has not moved, for example), a peptide may be worth discussing with a prescriber, with labs before and during, and a clear definition of success.
Is BPC-157 safe?
Its safety in humans has not been established in controlled trials. The FDA has cited limited human safety data and the potential for impurities in compounded peptides. The July 2026 advisory vote did not change its unapproved status.
Does MOTS-c help with weight loss?
In mice, MOTS-c prevented diet-induced obesity and insulin resistance. There are no controlled human trials showing weight or metabolic benefits yet.
Are CJC-1295 and ipamorelin good for fat loss?
They raise growth hormone and IGF-1, but fat loss in humans has not been demonstrated in controlled trials. A related compound raised muscle mass in older adults but also raised fasting glucose and lowered insulin sensitivity.
Is tesamorelin approved for belly fat?
Tesamorelin is FDA-approved to reduce excess abdominal fat in adults with HIV. Use in other people is off-label.
Can I buy these peptides legally?
None is an approved drug. Compounding status is under active FDA review. Products labeled "research use only" are not intended for human use and are not made under pharmacy oversight.
Considering a peptide? Start with the data. I help patients determine whether a peptide fits their metabolic picture, what the evidence supports, and what foundation work comes first. Book a discovery call.
This article is for educational purposes and is not medical advice. Peptide therapies require evaluation and prescription by a licensed clinician.
References
Regulatory status verified October 25, 2026.